Market size: what is knowable
Published estimates disagree by multiples. This page shows the spread rather than one number.
Estimate ranges by source, $B
| Source | Scope | Base | Target | CAGR | Quality | Note | Link |
|---|---|---|---|---|---|---|---|
| Meticulous Research | NAMs, broad (organ-chips, organoids, in silico and AI tox, NAM CRO services) | 2026 $1.8B to $2.4B | 2036 $12B to $16B | 21% | low quality | Indicative range, not a segmented model. CAGR stated as 20% to 22%. | meticulousresearch.com(opens in new tab) |
| Future Market Insights | NAM nonclinical testing | 2026 $0.745B | 2036 $1.897B | 9.8% | low quality | Overlapping scope with the Meticulous estimate, at roughly a third of its size. | futuremarketinsights.com(opens in new tab) |
| DataM Intelligence | Organ-on-a-chip | n/a | 2033 $2.663B | 36.12% | low quality | Base-year value not stated in the release. | openpr.com(opens in new tab) |
Key numbers
Organ-on-chip companies (Tracxn census)
Across 16 countries.
Equity raised by organ-on-chip companies, cumulative
67 equity rounds.
Organoid research model startups
79 funded; 19 at Series A or later.
NAM submissions to FDA CDER that are in silico or in vitro
15-year analysis of submissions. 3D and organ-chip models were less common than conventional in vitro models.
Animals used for EU regulatory testing, 2015 to 2023
Nearly 40% in chemical safety assessments.
Tools fully qualified through FDA ISTAND
Per FDA metrics dated Jan 1, 2026. Eight submissions were accepted during the pilot. Emulate filed a full package in Sep 2026.
NIH Complement-ARIE first awards
Plus about $20M for the validation network and a $7M challenge.
ARPA-H CATALYST budget for computational drug safety models
Over 4.5 years. Eight performer teams named Dec 2025.
Certara revenue, FY2024
Largest public pure play in biosimulation.
Simulations Plus revenue, FY2025
FY2026 guidance $79M to $82M.
Charles River revenue it called at risk from FDA's NAM push
Longer chronic NHP antibody studies. Management expected no immediate impact.
Price Sartorius paid for MatTek
MatTek had more than $20M of 2024 sales, so under 4x sales.
Emulate cumulative private funding
Last priced round an $82M Series E in 2021.
Why estimates differ: read the market size explainer.